Sign in
ACXP Stock Price, Chart, Stats & News
Acurx Pharmaceuticals, Inc.
Save
Acurx Pharmaceuticals, Inc. (ACXP) does not currently pay a dividend.
5.73M
Market cap
–
Current P/E
–
Forward P/E
ACXP chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -103.60% |
ROE | -215.55% |
D/E | – |
Interest coverage ratio | – |
ACXP valuation
P/E | – |
P/S | – |
P/B | 1.07x |
P/CF | 0.00x |
P/FCF | 0.00x |
P/OCF | 0.00x |
PEG | -0.02x |
EV multiple | -1286.15x |
About
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections.
Similar securities
Based on sector and market capitalization
Report issue